|Description||AZD-3147 is an extremely potent and selective dual inhibitor of mTORC1 and mTORC2. It exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. It has physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate.|
|Solubility||Soluble to 100 mM in DMSO and to 100 mM in 1eq. HCl|
|Application||AZD-3147 has physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||696.7±65.0 °C | Condition: Press: 760 Torr|
|Density||1.45±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) with an immunosuppressive activity which is comparable to that of rapamycin. It inhibits cyto...
Apitolisib, also known as GDC-0980 and RG7422; or GNE390, is a dual PI3 kinase/mTOR inhibitor, is also an orally available agent targeting phosphatidylinosit...
GNE-317 is a potent and selective PI3K inhibitor with potential anticncer activity. GNE-317 targets the PI3K pathway and can cross the Blood–Brain Barrier. GNE-...
WYE-125132, also known as WYE-132, is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor. WYE-132 inhibited mTORC1 and mTORC2 in diverse canc...
Dactolisib, also known as BEZ235, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BEZ235 speci...
Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. ...
CC-115, a DNA-PK and mTOR inhibitor, has been found to have probable anticarcinoma effect. IC50:13 nM and 21 nM for DNA-PK and mTOR respectively.
Palomid 529, also known as P529, is a novel PI3K/Akt/mTOR inhibitor. Palomid 529 (P529) inhibits the TORC1 and TORC2 complexes and shows both inhibition of Akt ...
NSC781406 demonstrates potent PI3K inhibition (PI3Kα IC50=2.0 nM) and is a highly potent mTOR inhibitor, with reasonable liver microsome stability.
CC-223, a mTOR kinase inhibitor, has been found to be effective in inducing the apoptosis and reducing the proliferation of tumor cells. It is still under Phase...
Desmethyl-VS-5584, a demethyl analogue of VS-5584, is a PI3K/mTOR kinase inhibitor for the treatment of cancer.
The functional target of QL-IX-55 is the ATP-binding site of TOR2 as evidenced by the discovery of resistant alleles of TOR2 through rational design and unbiase...
GDC-0349 is a small molecule anticaner drug candidate, being developed by Genentech. As of July 2012, Genentech has filed phase I trial of GDC-0349 for evaluati...
Torin 2 inhibits of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively.
AZD-3147 is an extremely potent and selective dual inhibitor of mTORC1 and mTORC2. It exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. It has ...
SMER18 is a small molecule enhancer of rapamycin. It act as a mTOR-independent autophagy inducer. It is a positive regulators of autophagy acting independently ...
WYE-687 is a potent and ATP-competitive and selective inhibitor of mTOR with IC50 of 7 nM.
AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. AZD2014 inhibits the activity o...
Omipalisib, also known as GSK2126458, is asmall-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic acti...
MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...